BTG Pactual Global Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

BTG Pactual Global Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-4,141	Closed	-$509K	–	65
2018 Q3	$509K	Sell	4,141 -8,390	-67%	-$952K	0.21%	39
2018 Q2	$1.23M	Buy	12,531 +666	+6%	+$59.6K	0.36%	40
2018 Q1	$984K	Buy	11,865 +1,393	+13%	+$118K	0.26%	41
2017 Q4	$813K	Buy	10,472 +354	+3%	+$24.1K	0.3%	35
2017 Q3	$620K	Sell	10,118 -704	-7%	-$37.1K	0.2%	45
2017 Q2	$498K	Buy	10,822 +2,667	+33%	+$129K	0.14%	53
2017 Q1	$353K	Buy	+8,155	New	+$349K	0.13%	58

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BTG Pactual Global Asset Management's NBIX Position: Q4 2018 in Review

BTG Pactual Global Asset Management sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 4,141 shares — an estimated $509K sold.

BTG Pactual Global Asset Management first reported a position in NBIX in Q1 2017 and held it in 7 quarters. The position peaked at $1.23M in Q2 2018. 331 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

BTG Pactual Global Asset Management reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
BTG Pactual Global Asset Management sold 4,141 Neurocrine Biosciences shares in Q4 2018, an estimated $509K.
BTG Pactual Global Asset Management first reported a position in Neurocrine Biosciences in Q1 2017 and held it in 7 quarters.
BTG Pactual Global Asset Management's Neurocrine Biosciences position peaked at $1.23M in Q2 2018.
331 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on BTG Pactual Global Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.